Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Robenacoxib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 9/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | NR1I3 | Q14994 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.43 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.38 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.38 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.38 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Robenacoxib SCHEMBL31121793 | 1.00 | PTGS2 (0.50) | PTGS2ABCB11PTGS1NR1I3PPARG | |
| SCHEMBL21650216 | 0.93 | PTGS2 (0.49) | PTGS2ABCB11PTGS1NR1I3PPARG | |
| SCHEMBL1034053 | 0.91 | PTGS2 (0.52) | PTGS2ABCB11PTGS1NR1I3PPARG | |
| Robenacoxib SCHEMBL6036188 | 0.87 | PTGS2 (0.40) | PTGS2ABCB11PTGS1NR1I3PPARG | |
| SCHEMBL6036430 | 0.87 | USP2 (0.46) | PTGS2ABCB11PTGS1NR1I3PPARG | |
| SCHEMBL6152172 | 0.87 | CXCL8 (0.46) | PTGS2ABCB11PTGS1NR1I3PPARG | |
| Robenacoxib SCHEMBL6061086 | 0.85 | PTGS2 (0.59) | PTGS2ABCB11PTGS1NR1I3PPARG | |
| SCHEMBL1034067 | 0.84 | PTGS2 (0.43) | PTGS2ABCB11PTGS1NR1I3PPARG | |
| SCHEMBL1032907 | 0.84 | PTGS2 (0.69) | PTGS2ABCB11PTGS1NR1I3PPARG | |
| SCHEMBL6036148 | 0.83 | PTGS2 (0.36) | PTGS2ABCB11PTGS1NR1I3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000741-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ACERAGEN INC (US) | 2026-01-01 | — | — | US | claimed |
| US-20250214927-A1 | AN IMPROVED PROCESS FOR PURIFICATION OF ROBENACOXIB | ALIVIRA ANIMAL HEALTH LIMITED (IN) | 2025-07-03 | — | — | US | claimed |
| US-20250066483-A1 | ANTI-PD-L1 ANTIBODY, ANTI-PD-1 ANTIBODY, AND THE USE OF INHIBITOR TARGETING PD-1/PD-L1 AND COX-2 INHIBITOR | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2025-02-27 | — | — | US | claimed |
| EP-4507694-A1 | SOFT CHEWABLE VETERINARY DOSAGE FORM | KRKA, d.d., Novo mesto (SI) | 2025-02-19 | — | — | EP | claimed |
| WO-2025031979-A1 | USE OF RIMCAZOLE TO TREAT CANCER | KYREXA LTD (GB) | 2025-02-13 | — | — | WO | claimed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | claimed |
| WO-2024052766-A1 | CYTOTOXIC AGENT FOR CHEMICAL DISBUDDING AND METHOD | Welfare Concepts Limited (NZ) | 2024-03-14 | — | — | WO | claimed |
| EP-3752201-B1 | SUSPENSION OF NANOSCALE, ORGANIC PARTICLES AND PROCESS FOR PRODUCTION THEREOF | UNIV FRIEDRICH ALEXANDER ER (DE) | 2023-11-22 | — | — | EP | claimed |
| WO-2023198476-A1 | SOFT CHEWABLE VETERINARY DOSAGE FORM | KRKA, D.D., NOVO MESTO (SI) | 2023-10-19 | — | — | WO | claimed |
| EP-1575581-A1 | COMBINATIONS OF VALSARTAN WITH COX-2 INHIBITORS | Novartis AG (CH) | 2005-09-21 | — | — | EP | claimed |
| WO-2004054575-A1 | COMBINATIONS OF VALSARTAN WITH COX-2 INHIBITORS | NOVARTIS AG (CH) | 2004-07-01 | — | — | WO | claimed |
| US-20040122254-A1 | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | NOVARTIS TIERGESUNDHEIT AG (CH) | 2004-06-24 | — | — | US | claimed |
| US-20030087942-A1 | Method for the treatment and prevention of cachexia | WASHINGTON UNIVERSITY | 2003-05-08 | — | — | US | claimed |
| EP-1007505-B1 | CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND DERIVATIVES | NOVARTIS AG (CH) | 2003-04-16 | — | — | EP | claimed |
| WO-2003020268-A1 | METHOD FOR THE TREATMENT AND PREVENTION OF CACHEXIA | WASHINGTON UNIVERSITY (US) | 2003-03-13 | — | — | WO | claimed |
| US-20020183391-A1 | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | NOVARTIS TIERGESUNDHEIT AG (CH) | 2002-12-05 | — | — | US | claimed |
| US-20020013369-A1 | Certain 5-alkyl-2arylaminophenylacetic acids and derivatives | NOVARTIS TIERGESUNDHEIT AG (CH) | 2002-01-31 | — | — | US | claimed |
| US-6310099-B1 | 5-METHYL OR ETHYL-2-(2-'CHLORO OR FLUORO OR TRIFLUROMETHYL-6'FLUORO OR CHLOROANILINO) PHENYLACETIC ACID OR SALT IS USED AS COX-2 SELECTIVE CYCLOOXYGENASE INHIBITOR | NOVARTIS AG (CH) | 2001-10-30 | — | — | US | claimed |
| US-6291523-B1 | SELECTIVE COX-2 CYCLOOXYGENASE INHIBITORS | NOVARTIS AG (CH) | 2001-09-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013369-A1 | Certain 5-alkyl-2arylaminophenylacetic acids and derivatives | HCAR2, CYP2F1, CYP2E1 | PTGS2 5/4885ABCB11 694/4885PTGS1 4/4885 |
| US-20040122254-A1 | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | CYP2F1, CYP2E1, PTGER1 | PTGS2 8/4885ABCB11 387/4885PTGS1 5/4885 |
| US-20030087942-A1 | Method for the treatment and prevention of cachexia | TNF, PTGES2, PTGS2 | PTGS2 3/4885ABCB11 4858/4885PTGS1 4/4885 |
| US-20020183391-A1 | Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives | CYP2F1, CYP2E1, PTGER1 | PTGS2 8/4885ABCB11 387/4885PTGS1 5/4885 |
| US-20260000741-A1 | METHOD OF AMELIORATING A PRO-INFLAMMATORY IMMUNOPHENOTYPE IN FARBER DISEASE SUBJECTS BY REPEATED ADMINISTRATION OF A RECOMBINANT HUMAN ACID CERAMIDASE | ASAH2, ASAH1, GBA2 | PTGS2 535/4885ABCB11 3038/4885PTGS1 1433/4885 |
| US-20250214927-A1 | AN IMPROVED PROCESS FOR PURIFICATION OF ROBENACOXIB | RDX, RCE1, MRPL21 | PTGS2 2643/4885ABCB11 828/4885PTGS1 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.